Tuberculosis Outbreaks in Prison Housing Units for HIV-Infected Inmates -- California, 1995-1996.
In both of the investigations, a positive tuberculin skin test (TST) was defined as an induration of [greater than or equal to]5 mm in contacts and/or HIV-infected persons. A TST conversion in a contact was defined as an increase of [greater than or equal to]5 mm from a documented negative to a positive TST within the previous 2 years. Only culture-positive pulmonary cases were considered infectious, and the infectious period was considered to begin 6 weeks before the date the culture-positive specimen was obtained (if the patient was asymptomatic) or the date of onset of symptoms consistent with TB.
On entry to the 500-person prison HIV housing unit in May 1995, the index case-patient was asymptomatic and anergic with a negative TST, and had a CD4 count of 6 cells/[micro]L, and a 1-cm calcified nodule on chest radiograph. Three sputum specimens, routinely collected on entry of all inmates into the housing unit, were smear- and culture-negative. Isoniazid (INH) was not prescribed because of baseline liver function test abnormalities. During the next 3 months he was treated with several courses of antibiotics, initially for laboratory-confirmed Pneumocystis carinii pneumonia (PCP) and then for episodic fever and cough. Each time his symptoms decreased, and one chest radiograph showed a new infiltrate that resolved with antibiotic treatment. In late August 1995, a chest radiograph revealed a new infiltrate, and sputum specimens were smear-positive for acid-fast bacillus (AFB). The patient was isolated and started on multidrug therapy for TB.
During September 1995-April 1996, drug-susceptible TB was diagnosed in 14 other inmates (including three parolees) and the HIV-infected wife of the index case-patient. Their M. tuberculosis isolates matched the isolate from the index case-patient by DNA fingerprint analysis. All inmates with TB resided on the same wing when one or more persons with TB with the outbreak strain had infectious cases. Of the 312 inmates who resided at least 1 day on the same wing as case-patients, 185 were available for screening in December; three had TST conversions but no disease. Inmates with TB disease were isolated and treated, and the proportion of the approximately 150 contacts in the wing receiving directly observed NH preventive therapy was increased from 14% in October 1995 to 60% in January 1996.
In January 1995, the index case-patient had a positive TST and received 6 months of preventive therapy while in a state prison. In December 1995, he was sent from the prison to a community hospital with cough, fever, a chest radiograph with infiltrate on the right, AEB smear-negative sputum specimens, and a newly diagnosed immunodeficiency (i.e., low CD4 count). He was empirically treated for PCP with trimethoprim/sulfamethoxazole, but his fever persisted. After the addition of prednisone, his fever resolved. On January 6, 1996, he was transferred from the hospital into an 180person HIV housing unit in a different prison (prison B). The community hospital staff indicated that no respiratory isolation was necessary. A chest radiograph on January 11, was normal. By January 19, cultures from sputum specimens and bone marrow aspirate obtained while he was at the community hospital (December 23, 1995) grew M. tuberculosis; he was placed in respiratory isolation, had a chest radiograph with a diffuse infiltrates b ilaterally, and was started on multidrug therapy for TB. He died from miliary TB on January 20. None of his sputum specimens obtained on January 8, January 10, and January 11 were AFB smear-positive.
During January-August 1996, drug-susceptible TB was diagnosed in 15 other inmates (including six parolees). The DNA fingerprints of M. tuberculosis isolates from all 15 matched the fingerprint of the isolate of the index case-patient. Analysis of sputum specimens from all 140 inmate contacts in the facility at the time of the investigation identified seven secondary case-patients whose chest radiographs were normal at the time of screening; five were asymptomatic. Screening of inmate contacts also detected 25 (18%) asymptomatic TST converters who did not have TB disease. These 25 received preventive therapy.
In both prisons, during the 4-month intervals between identification of the index case-patients and chest radiograph screening of all the contacts remaining in the housing unit, 190 inmates had been released. Of 56 (29%) who were reincarcerated in prisons or jails before they had had health evaluations in the community, follow-up information was available for the eight who were reincarcerated in jails; none had TB disease, and six accepted preventive therapy. The remaining 134 were referred to 22 local health jurisdictions. Of these 134, 76 (57%) were assessed; nine (12%) had culture-positive TB (three from prison A and six from prison B), each with the same outbreak strain of M. tuberculosis as found in the originating prison.
Secondary transmission may have occurred from both prison outbreaks to the community. The HIV-infected wife of the index case-patient in Prison A visited her husband for 4 hours per day on the 3 days before his placement in AFB isolation. Two months later, she developed smear- and culture-positive pulmonary TB with the outbreak strain. Her daughter, whose TST result was 0 mm on school entry in 1994, had a 28-mm reaction; she had not visited her father during his infectious period. An adult and two children aged <5 years who lived with a parolee from prison B while he was symptomatic all had TST results >10 mm but had no prior baseline.
Among prison employees who had contact with case-patients, TST conversions occurred in nine (2.8%) of 319 in prison A and 11(4.9%) of 223 in prison B. All 20 had had two documented negative TSTs during the previous 2 years, 19 had a baseline TST result of 0 mm, and 18 had a positive TST result of >10 mm. No employees had TB attributable to either outbreak strain.
Reported by: T Prendergast, MD, B Hwang, MD, R Alexander, San Bernardino County Health Dept, San Bernardino; T Charron, MD, E Lopez, MD, Solano County Health Dept, Vallejo; J Culton, MD, J Bick, MD, M Shalaby, MD, D Dewsnup, DO, H Meyer, MD, E Horowitz, MD, N Khouy, MD, California Dept of Corrections; J Mohle-Boetani, MD, S Royce, MD, D Chin, MD, S Petrillo, V Miguelino, E Desmond, PhD, R Harrison, MD, J Cone, MD, C Greene, M Joseph, S Waterman, MD, State Epidemiologist, California Dept of Health Svcs. Div of Tuberculosis Elimination, National Center for HIV STD, and TB Prevention, CDC.
Editorial Note: This report demonstrates that M. tuberculosis can spread rapidly among HIV-infected inmates in congregate living situations and to their visitors; disease developing in a visitor and a parolee may have led to secondary transmission in their household contacts. Containment required efforts of correctional and health department staff at the state and local levels to address the unique medical, custody, public health, and fiscal challenges posed by the outbreaks.
Updated policies and procedures for managing possible TB cases and their contacts are under development and implementation in correctional facilities and the community. The changes are to ensure that HIV-infected inmates with new radiographic abnormalities consistent with TB are placed in respiratory isolation, reported to the local health department and the central public health system of the prisons as having suspected TB, and started on multidrug therapy for TB even when another pulmonary process is diagnosed. These procedures will minimize the likelihood that HIV-infected persons with undiagnosed infectious TB (such as the index case-patient in the prison B outbreak) are transferred from jails, hospitals, or the community into prisons. The clinical course of the index case-patient in the prison A outbreak illustrates the challenge of detecting TB disease that develops in HIV-infected inmates after they have been cleared of having TB disease at entry to prison but develop it later. A TB evaluation should be initiated for HIV-infected inmates with respiratory symptoms who are diagnosed initially with conditions other than TB (1), even if TB has been excluded recently.
A prompt response to infectious TB cases is critical to minimize the transmission of TB and the development of disease among infected persons. All persons suspected to have infectious TB, including any person with a respiratory specimen that is smearpositive for AFB, must be placed immediately in respiratory isolation. A contact investigation must be initiated promptly. All HIV-infected contacts, regardless of TST status, should receive preventive therapy once TB disease is excluded (2,3).
Prevention of community spread (and reintroduction of undiagnosed infectious TB patients into correctional facilities) requires the rapid investigation of contacts in the facility. Inmate contacts should be evaluated and begun on treatment or preventive therapy before release from any facility, including hospitals or high-risk housing units. Joint efforts are underway in California to clarify roles and ensure that the infrastructure of prisons and health departments is adequate to track TB cases and suspected cases and to elicit, notify, and evaluate community contacts promptly (4,5).
The use of preventive therapy may need to be expanded beyond TST-positive inmates to certain HIV-infected persons with a negative TST. HIV-infected persons with a history of untreated or inadequately treated TB that healed should receive TB preventive treatment regardless of their age or results of TSTs 12). Primary prophylaxis for TST-negative HIV-infected persons with an ongoing and unavoidable high risk of exposure to M. tuberculosis should be considered (2,6,7). Following the TB outbreaks described in this report, the California Department of Corrections has recommended routine use of NH preventive therapy for all HIV-infected inmates with CD4 counts <100 cells/[micro]L, provided that such therapy is not contraindicated (7). The risks and benefits associated with primary prophylaxis in these settings need to be evaluated.
1. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care facilities, 1994. MMWR 1994:43(no. RR-13).
2. CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998:47(no. RR-20).
3. CDC. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1997;46(no. RR-12).
4. CDC. Prevention and control of tuberculosis in correctional facilities: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1996;45(no. RR-8).
5. California Department of Health Services, California Tuberculosis Controllers Association, and the California Conference of Local Health Officers. Guidelines for coordination of TB prevention and control by local and state health departments and California Department of Corrections. Berkeley, California: California Department of Health Services, 1998.
6. CDC. Anergy skin testing and preventive therapy for HIV-infected persons: revised recommendations. MMWR 1997;46(no. RR-15).
7. California Department of Corrections, Public Health Infectious Disease Advisory Committee. Tuberculosis protocols for human immunodeficiency virus infected inmates. Sacramento, California: California Department of Corrections, 1998..
|Printer friendly Cite/link Email Feedback|
|Publication:||Morbidity and Mortality Weekly Report|
|Date:||Feb 5, 1999|
|Previous Article:||Surveillance of Morbidity During Wildfires - Central Florida, 1998.|
|Next Article:||National Child Passenger Safety Week -- February 14-20, 1999.|